P Kosalka1, C Johnson2, M Turek2, J Sulpher3, A Law2, J Botros3, S Dent3,4, O Aseyev1,5. 1. Department of Medicine, Northern Ontario School of Medicine, Thunder Bay, ON. 2. Cardiology/Cardio-oncology, The Ottawa Hospital Cancer Centre, and Faculty of Medicine, University of Ottawa, Ottawa, ON. 3. Medical Oncology/Cardio-oncology, The Ottawa Hospital Cancer Centre, and Faculty of Medicine, University of Ottawa, Ottawa, ON. 4. Department of Medicine, Duke University, Durham, NC, U.S.A. 5. Regional Cancer Care Northwest, Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON.
Abstract
Background: Clinical trials have demonstrated an increased risk of cardiotoxicity in patients with breast cancer (bca) receiving trastuzumab-based therapy. Diabetes, dyslipidemia, and obesity are known risk factors for cardiovascular disease. Studies have yielded conflicting results about whether those factors increase the risk of cardiotoxicity in patients with bca receiving trastuzumab. Methods: In this retrospective cohort study, data were collected for 243 patients with bca positive for her2 (the human epidermal growth factor receptor 2) who were receiving trastuzumab and who were referred to The Ottawa Hospital Cardio-oncology Referral Clinic between 2008 and 2013. The data collected included patient demographics, reason for referral, cardiac function, chemotherapy regimen (including anthracycline use), and 3 comorbidities (diabetes, dyslipidemia, obesity). Rates of symptomatic cancer treatment-related cardiac dysfunction (sctcd) and asymptomatic decline in left ventricular ejection fraction (adlvef) were calculated for patients with and without the comorbidities of interest. Results: Of the 243 identified patients, 104 had either diabetes, dyslipidemia, or obesity. In that population, the most likely reason for referral to the cardio-oncology clinic was adlvef. The combination of 2 or 3 comorbidities significantly increased the incidence of sctcd in our population, reaching a rate of 67% for patients with obesity and dyslipidemia [relative risk (rr): 2.2; p = 0.04], 69% for patients with obesity and diabetes (rr: 2.3; p = 0.02), and 72% for patients with all 3 risk factors (rr: 2.4; p = 0.08). Conclusions: The combination of 2 or 3 comorbidities significantly increases the incidence of symptomatic cancer treatment-related cardiotoxicity. Patients with bca experiencing cancer treatment-related cardiotoxicity who have a history of diabetes, dyslipidemia, and obesity might require more proactive strategies for prevention, detection, and treatment of cardiotoxicity while receiving trastuzumab-based treatment.
Background: Clinical trials have demonstrated an increased risk of cardiotoxicity in patients with breast cancer (bca) receiving trastuzumab-based therapy. Diabetes, dyslipidemia, and obesity are known risk factors for cardiovascular disease. Studies have yielded conflicting results about whether those factors increase the risk of cardiotoxicity in patients with bca receiving trastuzumab. Methods: In this retrospective cohort study, data were collected for 243 patients with bca positive for her2 (the humanepidermal growth factor receptor 2) who were receiving trastuzumab and who were referred to The Ottawa Hospital Cardio-oncology Referral Clinic between 2008 and 2013. The data collected included patient demographics, reason for referral, cardiac function, chemotherapy regimen (including anthracycline use), and 3 comorbidities (diabetes, dyslipidemia, obesity). Rates of symptomatic cancer treatment-related cardiac dysfunction (sctcd) and asymptomatic decline in left ventricular ejection fraction (adlvef) were calculated for patients with and without the comorbidities of interest. Results: Of the 243 identified patients, 104 had either diabetes, dyslipidemia, or obesity. In that population, the most likely reason for referral to the cardio-oncology clinic was adlvef. The combination of 2 or 3 comorbidities significantly increased the incidence of sctcd in our population, reaching a rate of 67% for patients with obesity and dyslipidemia [relative risk (rr): 2.2; p = 0.04], 69% for patients with obesity and diabetes (rr: 2.3; p = 0.02), and 72% for patients with all 3 risk factors (rr: 2.4; p = 0.08). Conclusions: The combination of 2 or 3 comorbidities significantly increases the incidence of symptomatic cancer treatment-related cardiotoxicity. Patients with bca experiencing cancer treatment-related cardiotoxicity who have a history of diabetes, dyslipidemia, and obesity might require more proactive strategies for prevention, detection, and treatment of cardiotoxicity while receiving trastuzumab-based treatment.
Entities:
Keywords:
Breast cancer; cardiotoxicity; diabetes; dyslipidemia; her2 positivity; obesity; trastuzumab
Authors: Hart A Goldhar; Andrew T Yan; Dennis T Ko; Craig C Earle; George A Tomlinson; Maureen E Trudeau; Murray D Krahn; Monika K Krzyzanowska; Raveen S Pal; Christine Brezden-Masley; Scott Gavura; Kelly Lien; Kelvin K W Chan Journal: J Natl Cancer Inst Date: 2015-10-16 Impact factor: 13.506
Authors: Salvatore Mottillo; Kristian B Filion; Jacques Genest; Lawrence Joseph; Louise Pilote; Paul Poirier; Stéphane Rinfret; Ernesto L Schiffrin; Mark J Eisenberg Journal: J Am Coll Cardiol Date: 2010-09-28 Impact factor: 24.094
Authors: G Curigliano; D Cardinale; T Suter; G Plataniotis; E de Azambuja; M T Sandri; C Criscitiello; A Goldhirsch; C Cipolla; F Roila Journal: Ann Oncol Date: 2012-10 Impact factor: 32.976
Authors: Sandra M Swain; Michael S Ewer; Javier Cortés; Dino Amadori; David Miles; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; José Baselga Journal: Oncologist Date: 2013-03-08
Authors: Edward H Romond; Jong-Hyeon Jeong; Priya Rastogi; Sandra M Swain; Charles E Geyer; Michael S Ewer; Vikas Rathi; Louis Fehrenbacher; Adam Brufsky; Catherine A Azar; Patrick J Flynn; John L Zapas; Jonathan Polikoff; Howard M Gross; David D Biggs; James N Atkins; Elizabeth Tan-Chiu; Ping Zheng; Greg Yothers; Eleftherios P Mamounas; Norman Wolmark Journal: J Clin Oncol Date: 2012-09-17 Impact factor: 44.544
Authors: Jose Luis Zamorano; Patrizio Lancellotti; Daniel Rodriguez Muñoz; Victor Aboyans; Riccardo Asteggiano; Maurizio Galderisi; Gilbert Habib; Daniel J Lenihan; Gregory Y H Lip; Alexander R Lyon; Teresa Lopez Fernandez; Dania Mohty; Massimo F Piepoli; Juan Tamargo; Adam Torbicki; Thomas M Suter Journal: Eur Heart J Date: 2016-08-26 Impact factor: 29.983
Authors: Marilyn L Kwan; Richard K Cheng; Carlos Iribarren; Romain Neugebauer; Jamal S Rana; Mai Nguyen-Huynh; Zaixing Shi; Cecile A Laurent; Valerie S Lee; Janise M Roh; Hanjie Shen; Eileen Rillamas-Sun; Margarita Santiago-Torres; Dawn L Hershman; Lawrence H Kushi; Heather Greenlee Journal: J Clin Oncol Date: 2022-01-13 Impact factor: 50.717
Authors: Marco Gallo; Valerio Adinolfi; Viola Barucca; Natalie Prinzi; Valerio Renzelli; Luigi Barrea; Paola Di Giacinto; Rosaria Maddalena Ruggeri; Franz Sesti; Emanuela Arvat; Roberto Baldelli; Emanuela Arvat; Annamaria Colao; Andrea Isidori; Andrea Lenzi; Roberto Baldell; M Albertelli; D Attala; A Bianchi; A Di Sarno; T Feola; G Mazziotti; A Nervo; C Pozza; G Puliani; P Razzore; S Ramponi; S Ricciardi; L Rizza; F Rota; E Sbardella; M C Zatelli Journal: Rev Endocr Metab Disord Date: 2020-10-06 Impact factor: 6.514
Authors: Manuel U Ramirez; Kenysha Y J Clear; Zipporah Cornelius; Alaa Bawaneh; Yismeilin R Feliz-Mosquea; Adam S Wilson; Alistaire D Ruggiero; Nildris Cruz-Diaz; Lihong Shi; Bethany A Kerr; David R Soto-Pantoja; Katherine L Cook Journal: Physiol Rep Date: 2022-04
Authors: Tienush Rassaf; Matthias Totzeck; Johannes Backs; Carsten Bokemeyer; Michael Hallek; Denise Hilfiker-Kleiner; Andreas Hochhaus; Diana Lüftner; Oliver J Müller; Ulrich Neudorf; Roman Pfister; Stephan von Haehling; Lorenz H Lehmann; Johann Bauersachs Journal: Clin Res Cardiol Date: 2020-05-13 Impact factor: 5.460